Home › Companies › CRVS

Corvus Pharmaceuticals, Inc.

CRVS Lead: Phase 3 1 Biotech Distilled article ↓

Dermatology Oncology Protein Small Molecule

Most recent annual filing: 2026-03-12

Pipeline (4 active programs)

soquelitinib

CPI-818

Small Molecule Target: ITK

Peripheral T Cell Lymphoma Phase 3 oral
Atopic Dermatitis Phase 2 oral

ciforadenant

Small Molecule Target: A2A receptor

Renal Cell Carcinoma Phase 2 oral Kidney Cancer Research Consortium

mupadolimab

Protein Target: CD73

Undisclosed indication

Biotech Distilled coverage (1)

2026-05-19 Corvus Pharmaceuticals (CRVS) - Scientific Deep Dive for Soquelitinib and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.